[HTML][HTML] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

…, B Leyland-Jones, A Goldhirsch, M Untch… - … England Journal of …, 2005 - Mass Medical Soc
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and …

[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …

…, I Smith, B Thürlimann, M Toi, A Tutt, M Untch… - Annals of oncology, 2013 - Elsevier
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed
and endorsed substantial new evidence on aspects of the local and regional therapies for …

Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study

K Hermelink, M Untch, MP Lux, R Kreienberg, T Beck… - Cancer, 2007 - Wiley Online Library
BACKGROUND. It is believed widely that chemotherapy‐induced cognitive impairment occurs
in a subgroup of patients with breast cancer. However, recent reports have provided no …

[HTML][HTML] Trastuzumab emtansine for residual invasive HER2-positive breast cancer

…, S Loibl, EP Mamounas, M Untch… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

…, S Schmatloch, P Schrenk, A Staebler, M Untch - The lancet …, 2013 - thelancet.com
Background The optimum timing of sentinel-lymph-node biopsy for breast cancer patients
treated with neoadjuvant chemotherapy is uncertain. The SENTINA (SENTinel NeoAdjuvant) …

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

…, K Engels, K Mehta, V Nekljudova, M Untch - The lancet …, 2014 - thelancet.com
Background Preclinical data suggest that triple-negative breast cancers are sensitive to
interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, …

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

…, J Furlanetto, S Seiler, V Nekljudova, M Untch… - The Lancet …, 2021 - thelancet.com
Background The development of anti-HER2 antibody–drug conjugates opens new therapeutic
options for patients with breast cancer, including patients with low expression of HER2. …

[PDF][PDF] Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

M Untch, M Rezai, S Loibl, PA Fasching… - Journal of Clinical …, 2010 - researchgate.net
Purpose Trastuzumab, a humanized antibody against the human epidermal growth factor
receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively …

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2 …

M Untch, PA Fasching, GE Konecny… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by
paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth …

Event-free survival with pembrolizumab in early triple-negative breast cancer

…, R Hui, N Harbeck, M Takahashi, M Untch… - … England Journal of …, 2022 - Mass Medical Soc
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …